Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)

NCT02438007 is registered in ClinicalTrials.gov with LTN PHARMACEUTICALS, INC. as lead sponsor.

NCT NCT02438007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02438007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Lead sponsor
LTN PHARMACEUTICALS, INC.
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2015
Completion date
November 30, 2016
Enrollment
953 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer